Kodiak Sciences (KOD)
(Delayed Data from NSDQ)
$2.89 USD
-0.12 (-3.99%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.90 +0.01 (0.35%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Kodiak Sciences Inc. [KOD]
Reports for Purchase
Showing records 41 - 60 ( 127 total )
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
ARVO, the Global Ophthalmology Meeting Begins on Sunday, May 1st in Denver
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Eyes Wide Open - Lowering PT To $75 from $149, but Remaining Buy Rated.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Tracking Towards a 2023 BLA Filing -Could Be Worth Another Look - $149 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Kodiak Sciences Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department